High Manganese Content of Lipid NanoMn (LNM) by Microfluidic Technology for Enhancing Anti-Tumor Immunity
Jiawei Sun,
Jingjing Gong,
Lidong Gong,
Chuanda Zhu,
Longhao Li-Yang,
Jingya Wang,
Yuanyuan Yang,
Shiming Zhang,
Silu Liu,
Ji-Jun Fu,
Pengcheng Xu
Affiliations
Jiawei Sun
Department of Pharmaceutics, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
Jingjing Gong
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Lidong Gong
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Chuanda Zhu
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Longhao Li-Yang
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Jingya Wang
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Yuanyuan Yang
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Shiming Zhang
Beijing Key Laboratory of Tumor Systems Biology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Silu Liu
Department of Pharmaceutics, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
Ji-Jun Fu
School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
Pengcheng Xu
Department of Pharmaceutics, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
Immunotherapy is a clinically effective method for treating tumors. Manganese can activate the cGAS-STING signaling pathway and induce an anti-tumor immune response. However, its efficacy is hindered by non-specific distribution and low uptake rates. In this study, we employed microfluidic technology to design and develop an innovative preparation process, resulting in the creation of a novel manganese lipid nanoparticle (LNM). The lipid manganese nanoparticle produced in this process boasts a high manganese payload, excellent stability, the capacity for large-scale production, and high batch repeatability. LNM has effectively demonstrated the ability to activate the cGAS-STING signaling pathway, induce the production of pro-inflammatory cytokines, and inhibit tumor development. Notably, LNM does not require combination chemotherapy drugs or other immune activators. Therefore, LNM presents a safe, straightforward, and efficient strategy for anti-tumor immune activation, with the potential for scalable production.
